BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

International Wex Technologies (WXI): Peru Grants Authorization; Planning Clinical Trial Of Tetrodonin


10/19/2005 5:10:37 PM

International Wex Technologies Inc. (the "Company") is pleased to announce that through its subsidiary, Acro Pharm Corp. (formerly GlobalMed Corp.), and its distributor in Peru, a Sanitary Registry Authorization has been obtained for our product Tetrodonin(TM) (a product derived from our platform drug). This allows the Company to sell our product in Peru. Prior to sales, our distribution agreement states that clinical trials will be undertaken in that country. A clinical trial in Peru is now in the planning. The trial will be a double-blind, randomized, placebo-controlled, fixed repeated-dose efficacy and safety study to determine the efficacy of Tetrodonin(TM) in decreasing drug use and the severity of drug withdrawal symptoms and to assess its safety and tolerability for therapeutic use in drug-dependent subjects. Acro Pharm Corp. will coordinate the project with the Peruvian distributor to conduct the clinical trial. The timeline for commencement of this trial has not yet been established. Further details will be announced as the project progresses.

Read at CCNMatthews

   
Addiction

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES